drugset / Trial / NCT07281001
A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
Timeline
- Start
- 2025-12
- Primary completion
- 2026-05
- Completion
- 2026-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | 5.4 mg/kg | Intravenous |